JUPITER enrolled men 50 years of age and women 60 years of age with high-sensitivity C-reactive pro- tein values 2.0 mg/L and LDL-C <130 mg/dL. Participants randomly assigned to 20 mg per day of rosuvastatin achieved a median LDL-C reduc- tion of 50% and a highly significant ASCVD risk Importantly, the mag- nitude of the percent LDL-C reduction achieved The USPSTF systematic review of statin therapy in primary prevention showed a reduced risk of all-cause and cardio- vascular mortality and ASCVD events and noted greater absolute benefits in those at greater base- consistent with other high-quality sys- tematic reviews and meta-analyses.S4.3-2,S4.3-8,S4.3-35 This underscores the need for aggressive and safe risk reduction in the highest-risk groups and the need for follow-up LDL-C testing to determine adherence and adequacy of effect of the statin 3. Most patients 40 to 75 years of age with diabe- tes are at intermediate or high risk (PCE 7.5% 10-year risk) of ASCVD events.S4.3-15,S4.3-16,S4.3-18 Three of 4 double-blinded primary-prevention RCTs of moderate statin therapy in large cohorts with diabetes in this age range showed significant reductions in ASCVD events.S4.3-11,S4.3-12,S4.3-14,S4.3-17 A meta-analysis of these trials found that moderate- intensity statin therapy was associated with a risk reduction of 25%,S4.3-13 similar to people without diabetes and with no apparent difference in ben- efit between type 1 diabetes mellitus and T2DM. Therefore, moderate-intensity statin therapy is indicated for primary prevention in patients 40 to 75 years of age with diabetes. 4. Patients with primary severe hypercholesterolemia (LDL-C 190 mg/dL [ 4.9 mmol/L]) have a high risk of ASCVDS4.3-23 and premature and recurrent coronary events. 